CN105734152A - 检测人srpk2基因的表达水平的特异引物对及其应用 - Google Patents
检测人srpk2基因的表达水平的特异引物对及其应用 Download PDFInfo
- Publication number
- CN105734152A CN105734152A CN201610246705.0A CN201610246705A CN105734152A CN 105734152 A CN105734152 A CN 105734152A CN 201610246705 A CN201610246705 A CN 201610246705A CN 105734152 A CN105734152 A CN 105734152A
- Authority
- CN
- China
- Prior art keywords
- measured
- gene
- people
- srpk2
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 131
- 101100366652 Homo sapiens SRPK2 gene Proteins 0.000 title claims description 129
- 201000007270 liver cancer Diseases 0.000 claims abstract description 56
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 56
- 238000001514 detection method Methods 0.000 claims abstract description 42
- 101000826077 Homo sapiens SRSF protein kinase 2 Proteins 0.000 claims abstract description 11
- 210000001519 tissue Anatomy 0.000 claims description 107
- 210000004185 liver Anatomy 0.000 claims description 84
- 230000008520 organization Effects 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 239000002299 complementary DNA Substances 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 16
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 102100023015 SRSF protein kinase 2 Human genes 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 230000008034 disappearance Effects 0.000 claims description 8
- 238000003757 reverse transcription PCR Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000012797 qualification Methods 0.000 claims description 4
- 238000013467 fragmentation Methods 0.000 claims description 2
- 238000006062 fragmentation reaction Methods 0.000 claims description 2
- 210000005228 liver tissue Anatomy 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 abstract 4
- 102000053602 DNA Human genes 0.000 abstract 2
- 108020004682 Single-Stranded DNA Proteins 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 11
- 101150112014 Gapdh gene Proteins 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610246705.0A CN105734152B (zh) | 2016-04-20 | 2016-04-20 | 检测人srpk2基因的表达水平的特异引物对及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610246705.0A CN105734152B (zh) | 2016-04-20 | 2016-04-20 | 检测人srpk2基因的表达水平的特异引物对及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105734152A true CN105734152A (zh) | 2016-07-06 |
CN105734152B CN105734152B (zh) | 2019-02-26 |
Family
ID=56255678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610246705.0A Active CN105734152B (zh) | 2016-04-20 | 2016-04-20 | 检测人srpk2基因的表达水平的特异引物对及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105734152B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108728540A (zh) * | 2018-06-11 | 2018-11-02 | 北京大学人民医院 | 定量检测pard3基因表达的引物和探针及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002807A2 (en) * | 2000-06-30 | 2002-01-10 | Epigenomics Ag | Diagnosis of diseases associated with cell signalling |
CN101565752A (zh) * | 2009-05-27 | 2009-10-28 | 张鹏辉 | 肿瘤多药耐药相关基因的荧光定量pcr检测试剂盒及其检测方法 |
-
2016
- 2016-04-20 CN CN201610246705.0A patent/CN105734152B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002807A2 (en) * | 2000-06-30 | 2002-01-10 | Epigenomics Ag | Diagnosis of diseases associated with cell signalling |
CN101565752A (zh) * | 2009-05-27 | 2009-10-28 | 张鹏辉 | 肿瘤多药耐药相关基因的荧光定量pcr检测试剂盒及其检测方法 |
Non-Patent Citations (1)
Title |
---|
YINYINGLU ET AL.: "Alternative Splicing of the Cell Fate Determinant Numb in Hepatocellular Carcinoma", 《HEPATOLOGY》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108728540A (zh) * | 2018-06-11 | 2018-11-02 | 北京大学人民医院 | 定量检测pard3基因表达的引物和探针及其应用 |
CN108728540B (zh) * | 2018-06-11 | 2022-03-22 | 北京大学人民医院 | 定量检测pard3基因表达的引物和探针及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105734152B (zh) | 2019-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peng et al. | Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma | |
AU2020100457A4 (en) | USE OF circRNA IN PREPARATION OF DIAGNOSTIC KIT FOR HEPATOCELLULAR CARCINOMA AND KIT USING circRNA | |
CN106591438A (zh) | 一种用于检测Her2基因的核酸组合、试剂盒及应用 | |
Zhao et al. | Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer | |
Mongre et al. | Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma | |
CN106047989A (zh) | 一种环状rna在结直肠癌检验标志物中的应用 | |
Zhu et al. | MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells. | |
CN111304326B (zh) | 检测及靶向lncRNA生物标志物的试剂及其在肝细胞癌中的应用 | |
Xu et al. | Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2 | |
CN109055555A (zh) | 一种肺癌早期转移诊断标志物及其试剂盒和应用 | |
CN107586842A (zh) | 一种用于肾透明细胞癌诊治的生物标志物 | |
CN108531586A (zh) | 一种与乳腺癌辅助诊断相关的位于X染色体上的循环miRNA标志物及其应用 | |
CN107312865B (zh) | Loc100130111在制备骨肉瘤诊断产品、治疗药物中的用途 | |
CN107475386B (zh) | 用于诊治骨肉瘤的长链非编码rna标志物 | |
Ma et al. | KCNMA1-AS1 attenuates apoptosis of epithelial ovarian cancer cells and serves as a risk factor for poor prognosis of epithelial ovarian cancer. | |
CN107190005B (zh) | lncRNA作为生物标志物在肺腺癌诊治中的应用 | |
CN105154541A (zh) | miRNA在急性髓系白血病诊断和治疗中的应用 | |
CN105734152A (zh) | 检测人srpk2基因的表达水平的特异引物对及其应用 | |
CN105463117A (zh) | 检测人riok2基因表达量和相对表达量的引物对 | |
CN105603117B (zh) | miR-3613用于区分肺鳞癌转移与非转移的miRNA标志物 | |
CN105506131A (zh) | 检测人aeg-1基因表达量和相对表达量的引物对 | |
CN105821126A (zh) | 检测人pak2基因的表达水平的特异引物对及其应用 | |
CN105695458A (zh) | 检测人hk2基因的表达水平的特异引物对及其应用 | |
CN105603115B (zh) | 肺鳞癌转移诊治标志物 | |
CN109371136A (zh) | 一种与肺腺癌相关的lncRNA及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 199, Dongping Street, Suzhou Industrial Park, Wuzhong District, Suzhou City, Jiangsu Province, 215,125 Patentee after: Suzhou Gemma Biotechnology Co.,Ltd. Address before: 215123 No. 199 Dongping street, Suzhou Industrial Park, Suzhou, Jiangsu. Patentee before: SUZHOU GENOARRAY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240205 Address after: 200131, Building 13, No. 368 Zhangjiang Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai Patentee after: SHANGHAI GENEPHARMA CO.,LTD. Country or region after: China Address before: No. 199, Dongping Street, Suzhou Industrial Park, Wuzhong District, Suzhou City, Jiangsu Province, 215,125 Patentee before: Suzhou Gemma Biotechnology Co.,Ltd. Country or region before: China |